slides · global inventory
Problem Agitate Solution
Arc collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 26,550
Current window 1,531-1,560
Pages 885
Rows per page 30
Arc
1,531-1,560 of 26,550
06
The slide uses a comparison framework to contrast the data availability between small molecule and biologic drug discovery.Absci | Investor Conference Presentation Deck | 21 slides · absci
Conference presentation Investor relations Beat · ProblemLoop · Cost Of Inaction2 hits
07
The slide uses a process flow to explain the technical advantage of the company's platform.Absci | Investor Conference Presentation Deck | 21 slides · absci
Conference presentation Investor relations Beat · AgitateLoop · Cost Of Inaction2 hits
11
The chart displays efficacy data for a drug candidate, noting the impact of anti-drug antibodies (ADAs) on the third cohort.Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution2 hits
12
Aeglea BioTherapeutics | Investor Presentation Deck | 37 slidesAeglea BioTherapeutics | Investor Presentation Deck | 37 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution2 hits
06
Aeglea BioTherapeutics | Investor Presentation Deck | 38 slidesAeglea BioTherapeutics | Investor Presentation Deck | 38 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Problem2 hits
08
The slide uses a pie chart to segment patients and a timeline/number line to show age of diagnosis, followed by key metrics on clinical complications.Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Problem2 hits
09
Includes a biological process diagram showing intracellular vs plasma metabolism.Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution2 hits
10
The slide outlines a multi-part clinical trial design with specific dosing cohorts and eligibility requirements.Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution Approach2 hits
11
The chart displays efficacy data for a drug candidate (pegtarviliase) across different dosage cohorts.Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution Approach2 hits
09
Includes two testimonials from Key Opinion Leaders (KOLs) to emphasize the difficulty of treatment compliance.Aeglea BioTherapeutics | Investor Presentation Deck | 39 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Problem2 hits
07
Uses a geographic map and a nested circle diagram to illustrate the treatment gap.Arbutus Biopharma | Investor Presentation Deck | 28 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction2 hits
10
The slide outlines the study structure for a clinical trial, categorizing cohorts by dosage and patient status (HBV DNA +/-).Arbutus Biopharma | Investor Presentation Deck | 28 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · Solution2 hits
11
Data presented at EASL 2022 and AASLD 2022.Arbutus Biopharma | Investor Presentation Deck | 28 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · Solution2 hits
12
The slide displays longitudinal data for cohorts E, F, I, J, G, and K, highlighting individual patient responses and key clinical outcomes.Arbutus Biopharma | Investor Presentation Deck | 28 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · Solution2 hits
13
The slide displays 8 individual patient case studies (Pt 46, 51, 52, 53, 56, 58, 59, 60, 61).Arbutus Biopharma | Investor Presentation Deck | 28 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · Solution2 hits
14
Data presented at EASL 2022. Shows longitudinal patient data for patients 42, 43, and 48.Arbutus Biopharma | Investor Presentation Deck | 28 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · Solution2 hits
17
The slide uses a timeline-based process diagram to illustrate the clinical trial flow.Arbutus Biopharma | Investor Presentation Deck | 28 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · Solution2 hits
18
The slide outlines a clinical trial design with two main arms involving AB-729, VTP-300, and optional Nivolumab.Arbutus Biopharma | Investor Presentation Deck | 28 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · Solution2 hits
19
The slide details a specific licensing deal, including financial terms and partner background.Arbutus Biopharma | Investor Presentation Deck | 28 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · Solution2 hits
20
The slide uses a three-column layout to explain the scientific basis and benefits of the drug.Arbutus Biopharma | Investor Presentation Deck | 28 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · SolutionLoop · Jobs To Be Done2 hits
21
Includes IC50 value and IFN-y fold increase data from patient samples.Arbutus Biopharma | Investor Presentation Deck | 28 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · SolutionLoop · Jobs To Be Done2 hits
22
The slide uses a three-column layout to highlight the core benefits of the product.Arbutus Biopharma | Investor Presentation Deck | 28 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · SolutionLoop · Jobs To Be Done2 hits
23
Includes both longitudinal efficacy data (line chart) and pharmacokinetic data (bar charts) comparing plasma vs liver concentrations.Arbutus Biopharma | Investor Presentation Deck | 28 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · Solution2 hits
24
Arbutus Biopharma | Investor Presentation Deck | 28 slidesArbutus Biopharma | Investor Presentation Deck | 28 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · Solution2 hits
25
The slide maps the viral genome to specific drug targets and highlights partnerships with X-Chem and Proteros.Arbutus Biopharma | Investor Presentation Deck | 28 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · Solution2 hits
26
The slide highlights key therapeutic advantages of the candidate drug.Arbutus Biopharma | Investor Presentation Deck | 28 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · Solution2 hits
27
The slide uses a table to present a timeline of clinical milestones.Arbutus Biopharma | Investor Presentation Deck | 28 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · Solution2 hits
28
Arbutus Biopharma | Investor Presentation Deck | 28 slidesArbutus Biopharma | Investor Presentation Deck | 28 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · Solution2 hits
05
Benson Hill | Results Presentation Deck | 23 slidesBenson Hill | Results Presentation Deck | 23 slides · Benson Hill
Conference presentation Investor relations Beat · ProblemLoop · Golden Circle2 hits
17
The slide presents a mix of financial metrics and qualitative business updates.Silicon Valley Bank | Investor Presentation Deck | 30 slides · SVB
Conference presentation Investor relations Beat · ProblemLoop · Cost Of Inaction2 hits